Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Filings indexed 1,237 across all filing types
Latest filing 2025-01-30 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Integrated Filing- Financial
Regulatory Filings
2025-01-30 English
Please find attached Intergrated Filing (Financial) for the quarter and nine months ended December 31, 2024
Regulatory Filings
2025-01-30 English
Please find attached herewith the copies of the Newspaper publication regarding the Unaudited Standalone and Consolidated Financial Results of the Company of the Company for the quarter ....
Regulatory Filings
2025-01-30 English
Copy of Newspaper Publication
Regulatory Filings
2025-01-30 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 100% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2024. It is addressed to stock exchanges and confirms dematerialisation activities and related compliance. The document is a certification letter from the Registrar and Share Transfer Agent to the company and stock exchanges. It does not contain financial statements or substantive financial data, nor is it a report or announcement of financial results. It is primarily a regulatory compliance certificate. According to the CERTIFICATION RULE, such officer certifications or confirmation letters should be classified as Regulatory Filings (RNS). The document length is short (3187 characters), and it is not an announcement of a report but a certificate itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-01-29 English
Please find attached herewith a certificate received from MUFG Intime India Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities Exchange ....
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2024. It is addressed to stock exchanges and confirms dematerialisation activities and related compliance. The document is a formal attestation or certification from the Registrar and Share Transfer Agent, MUFG Intime India Private Limited, confirming regulatory compliance for a specific quarter. It does not contain financial statements, management discussion, or detailed financial data. The document length is 3187 characters, which is relatively short and consistent with a certification letter rather than a full report. According to the rules, such certification documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report or other financial report types.
2025-01-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.